Century Therapeutics Stock Math Operators Price Series Multiplication
| IPSC Stock | USD 2.34 -0.16 -6.40% |
| Symbols |
Operator |
Century Therapeutics Technical Analysis Modules
Most technical analysis of Century Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Century from various momentum indicators to cycle indicators. When you analyze Century charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Methodology
Unless otherwise specified, financial data for Century Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Century (USA Stocks:IPSC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Century Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Century Therapeutics is covered by 5 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include RBC Capital Markets, Barclays, HSBC Global Research, Wells Fargo Securities, Bank of America Securities, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardBecome your own money manager
Did you try this?
Run Portfolio Prophet Now
Portfolio ProphetUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Cash Cows Invested few shares | |
 | Blockchain Invested few shares | |
 | Advertising Invested few shares | |
 | Investor Favorites Invested few shares | |
 | Corona Opportunity Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Artificial Intelligence Invested few shares | |
 | Adviser Favorites Invested few shares | |
 | Hedge Favorites Invested over 20 shares | |
More Resources for Century Stock Analysis
Reviewing Century Therapeutics commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Century Therapeutics' operating context. Outlined below are key reports that provide context for Century Therapeutics Stock: Earnings Share -0.32 | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |